Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols

Daisuke Tomizawa, Tomoyuki Watanabe, Ryoji Hanada, Keizo Horibe, Yasuo Horikoshi, Shotaro Iwamoto, Akitoshi Kinoshita, Hiroshi Moritake, Hideki Nakayama, Akira Shimada, Takashi Taga, Hiroyuki Takahashi, Akio Tawa, Kiminori Terui, Hiroki Hori, Yoshifumi Kawano, Atsushi Kikuta, Atsushi Manabe, Souichi Adachi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

As past studies of adolescent and young adults (AYA) with acute myeloid leukemia (AML) reported conflicting results, we conducted a retrospective analysis using data from three Japanese pediatric AML studies. Among the 782 patients with de novo AML, 44 were classified as AYA (age ≥15 years at diagnosis), 164 as infants (0–1 year), 413 as younger children (2–11 years), and 161 as older children (12–14 years). While the 5-year event-free survival rate of AYA was not different among the groups, the five-year survival rate (54.7 %) was significantly lower than that of the other three groups (P = 0.019): 68.7 % for infants, 73.2 % for younger children, and 75.5 % for older children. No difference in the 5-year cumulative incidence of relapse was observed, but treatment-related death (TRD) of AYA was significantly higher (29.4 %) than that in infants (14.8 %), younger children (10.2 %), and older children (13.8 %). Multivariate analysis showed age ≥15 years old at diagnosis was associated with both poor survival rate and high TRD. Adolescents with AML had inferior survival due to a higher incidence of TRD, especially after failure of initial frontline treatment.

Original languageEnglish
Pages (from-to)318-326
Number of pages9
JournalInternational Journal of Hematology
Volume102
Issue number3
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Acute Myeloid Leukemia
Pediatrics
Young Adult
Survival Rate
Incidence
Therapeutics
Disease-Free Survival
Multivariate Analysis
Recurrence
Survival

Keywords

  • Acute myeloid leukemia
  • Adolescents
  • Children

ASJC Scopus subject areas

  • Hematology

Cite this

Tomizawa, D., Watanabe, T., Hanada, R., Horibe, K., Horikoshi, Y., Iwamoto, S., ... Adachi, S. (2015). Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols. International Journal of Hematology, 102(3), 318-326. https://doi.org/10.1007/s12185-015-1825-x

Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols. / Tomizawa, Daisuke; Watanabe, Tomoyuki; Hanada, Ryoji; Horibe, Keizo; Horikoshi, Yasuo; Iwamoto, Shotaro; Kinoshita, Akitoshi; Moritake, Hiroshi; Nakayama, Hideki; Shimada, Akira; Taga, Takashi; Takahashi, Hiroyuki; Tawa, Akio; Terui, Kiminori; Hori, Hiroki; Kawano, Yoshifumi; Kikuta, Atsushi; Manabe, Atsushi; Adachi, Souichi.

In: International Journal of Hematology, Vol. 102, No. 3, 01.07.2015, p. 318-326.

Research output: Contribution to journalArticle

Tomizawa, D, Watanabe, T, Hanada, R, Horibe, K, Horikoshi, Y, Iwamoto, S, Kinoshita, A, Moritake, H, Nakayama, H, Shimada, A, Taga, T, Takahashi, H, Tawa, A, Terui, K, Hori, H, Kawano, Y, Kikuta, A, Manabe, A & Adachi, S 2015, 'Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols', International Journal of Hematology, vol. 102, no. 3, pp. 318-326. https://doi.org/10.1007/s12185-015-1825-x
Tomizawa, Daisuke ; Watanabe, Tomoyuki ; Hanada, Ryoji ; Horibe, Keizo ; Horikoshi, Yasuo ; Iwamoto, Shotaro ; Kinoshita, Akitoshi ; Moritake, Hiroshi ; Nakayama, Hideki ; Shimada, Akira ; Taga, Takashi ; Takahashi, Hiroyuki ; Tawa, Akio ; Terui, Kiminori ; Hori, Hiroki ; Kawano, Yoshifumi ; Kikuta, Atsushi ; Manabe, Atsushi ; Adachi, Souichi. / Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols. In: International Journal of Hematology. 2015 ; Vol. 102, No. 3. pp. 318-326.
@article{e64aab6e40474a1ea4f0bf8ba6f452a9,
title = "Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols",
abstract = "As past studies of adolescent and young adults (AYA) with acute myeloid leukemia (AML) reported conflicting results, we conducted a retrospective analysis using data from three Japanese pediatric AML studies. Among the 782 patients with de novo AML, 44 were classified as AYA (age ≥15 years at diagnosis), 164 as infants (0–1 year), 413 as younger children (2–11 years), and 161 as older children (12–14 years). While the 5-year event-free survival rate of AYA was not different among the groups, the five-year survival rate (54.7 {\%}) was significantly lower than that of the other three groups (P = 0.019): 68.7 {\%} for infants, 73.2 {\%} for younger children, and 75.5 {\%} for older children. No difference in the 5-year cumulative incidence of relapse was observed, but treatment-related death (TRD) of AYA was significantly higher (29.4 {\%}) than that in infants (14.8 {\%}), younger children (10.2 {\%}), and older children (13.8 {\%}). Multivariate analysis showed age ≥15 years old at diagnosis was associated with both poor survival rate and high TRD. Adolescents with AML had inferior survival due to a higher incidence of TRD, especially after failure of initial frontline treatment.",
keywords = "Acute myeloid leukemia, Adolescents, Children",
author = "Daisuke Tomizawa and Tomoyuki Watanabe and Ryoji Hanada and Keizo Horibe and Yasuo Horikoshi and Shotaro Iwamoto and Akitoshi Kinoshita and Hiroshi Moritake and Hideki Nakayama and Akira Shimada and Takashi Taga and Hiroyuki Takahashi and Akio Tawa and Kiminori Terui and Hiroki Hori and Yoshifumi Kawano and Atsushi Kikuta and Atsushi Manabe and Souichi Adachi",
year = "2015",
month = "7",
day = "1",
doi = "10.1007/s12185-015-1825-x",
language = "English",
volume = "102",
pages = "318--326",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols

AU - Tomizawa, Daisuke

AU - Watanabe, Tomoyuki

AU - Hanada, Ryoji

AU - Horibe, Keizo

AU - Horikoshi, Yasuo

AU - Iwamoto, Shotaro

AU - Kinoshita, Akitoshi

AU - Moritake, Hiroshi

AU - Nakayama, Hideki

AU - Shimada, Akira

AU - Taga, Takashi

AU - Takahashi, Hiroyuki

AU - Tawa, Akio

AU - Terui, Kiminori

AU - Hori, Hiroki

AU - Kawano, Yoshifumi

AU - Kikuta, Atsushi

AU - Manabe, Atsushi

AU - Adachi, Souichi

PY - 2015/7/1

Y1 - 2015/7/1

N2 - As past studies of adolescent and young adults (AYA) with acute myeloid leukemia (AML) reported conflicting results, we conducted a retrospective analysis using data from three Japanese pediatric AML studies. Among the 782 patients with de novo AML, 44 were classified as AYA (age ≥15 years at diagnosis), 164 as infants (0–1 year), 413 as younger children (2–11 years), and 161 as older children (12–14 years). While the 5-year event-free survival rate of AYA was not different among the groups, the five-year survival rate (54.7 %) was significantly lower than that of the other three groups (P = 0.019): 68.7 % for infants, 73.2 % for younger children, and 75.5 % for older children. No difference in the 5-year cumulative incidence of relapse was observed, but treatment-related death (TRD) of AYA was significantly higher (29.4 %) than that in infants (14.8 %), younger children (10.2 %), and older children (13.8 %). Multivariate analysis showed age ≥15 years old at diagnosis was associated with both poor survival rate and high TRD. Adolescents with AML had inferior survival due to a higher incidence of TRD, especially after failure of initial frontline treatment.

AB - As past studies of adolescent and young adults (AYA) with acute myeloid leukemia (AML) reported conflicting results, we conducted a retrospective analysis using data from three Japanese pediatric AML studies. Among the 782 patients with de novo AML, 44 were classified as AYA (age ≥15 years at diagnosis), 164 as infants (0–1 year), 413 as younger children (2–11 years), and 161 as older children (12–14 years). While the 5-year event-free survival rate of AYA was not different among the groups, the five-year survival rate (54.7 %) was significantly lower than that of the other three groups (P = 0.019): 68.7 % for infants, 73.2 % for younger children, and 75.5 % for older children. No difference in the 5-year cumulative incidence of relapse was observed, but treatment-related death (TRD) of AYA was significantly higher (29.4 %) than that in infants (14.8 %), younger children (10.2 %), and older children (13.8 %). Multivariate analysis showed age ≥15 years old at diagnosis was associated with both poor survival rate and high TRD. Adolescents with AML had inferior survival due to a higher incidence of TRD, especially after failure of initial frontline treatment.

KW - Acute myeloid leukemia

KW - Adolescents

KW - Children

UR - http://www.scopus.com/inward/record.url?scp=84941259016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941259016&partnerID=8YFLogxK

U2 - 10.1007/s12185-015-1825-x

DO - 10.1007/s12185-015-1825-x

M3 - Article

VL - 102

SP - 318

EP - 326

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -